Alternative Medicine Research Today is a free monthly online journal that collates and summarizes the latest research about Alternative Medicine, including details on complementary medicine, alternative therapies, homeopathy.

Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.

Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH

Neurologische Universitätsklinik, Essen, Germany. h.diener@uni-essen.de

The efficacy and tolerability of a CO(2)-extract of feverfew (MIG-99, 6.25 mg t.i.d.) for migraine prevention were investigated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients (N = 170 intention-to-treat; MIG-99, N = 89; placebo, N = 81) suffering from migraine according to International Headache Society criteria were treated for 16 weeks after a 4-week baseline period. The primary endpoint was the average number of migraine attacks per 28 days during the treatment months 2 and 3 compared with baseline. Safety parameters included adverse events, laboratory parameters, vital signs and physical examination. The migraine frequency decreased from 4.76 by 1.9 attacks per month in the MIG-99 group and by 1.3 attacks in the placebo group (P = 0.0456). Logistic regression of responder rates showed an odds ratio of 3.4 in favour of MIG-99 (P = 0.0049). Adverse events possibly related to study medication were 9/107 (8.4%) with MIG-99 and 11/108 (10.2%) with placebo (P = 0.654). MIG-99 is effective and shows a favourable benefit-risk ratio.

Published 19 October 2005 in Cephalalgia, 25(11): 1031-41.
Full-text of this article is available online (may require subscription).

© 2005-2008 Alternative Medicine Research Today. All Rights Reserved.